Clinical Trial Update: A Study of the Safety and Efficacy of Single-agent Carlumab (an Anti-Chemokine Ligand 2 [CCL2]) in Participants With Metastatic Castrate-Resistant Prostate Cancer [Phase 2]

View source ↗

Summary

Phase 2 study of single-agent Carlumab in metastatic castration-resistant prostate cancer completed with results posted in 2013.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer
• Prostate Cancer

Drugs mentioned

• Carlumab (Carlumab)

Snippet

Sponsor: Centocor Research & Development, Inc. | Conditions: Prostate Cancer | Phase 2 | Status: COMPLETED | Results posted: 2013-05-20